PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to shrink advanced stomach tumors
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and lenvatinib (which blocks enzymes that help tumors grow)—can shrink tumors in people with advanced stomach or gastroesophageal cancer that …
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 21:17 UTC
-
New drug targets rare genetic flaws in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a drug called avapritinib in people with advanced solid tumors that have certain genetic changes (CKIT or PDGFRA mutations). The goal is to see if the drug can shrink or control the cancer. About 50 adults with cancers like melanoma, sarcoma, or breast, lung, or …
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC